cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1495Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESКлиническая, липид-нормализующая и плейотропная эффективность розувастатина; обзор серии исследований GALAXYClinical, lipid-lowering, and pleiotropic effectiveness of rosuvastatin: a review of the GALAXY programme resultsБритовА. Н.BritovA. N.abritov@gnicpm.ruЧупинаМ. П.ChupinaM. P.ФГУ Государственный научно-исследовательский центр профилактической медициныState Research Centre for Preventive Medicine201120022011101104109Copyright © Бритов А.Н., Чупина М.П., 20112011Бритов А.Н., Чупина М.П.Britov A.N., Chupina M.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1495

В статье представлен обзор результатов законченной международной программы GALAXY, представляющей собой серию клинических, как правило, сравнительных исследований, сопоставляющих различные статины. Эти исследования показали преимущество розувастатина в нормализации показателей липидного обмена, маркеров воспаления и обратного развития атеросклероза в коронарных артериях и магистральных артериях головы. Лекарственные формы розувастатина весьма перспективны для профилактики тяжелых органных поражений у больных атеросклерозом на всех стадиях его развития.

The paper reviews the results of the GALAXY international programme, a series of clinical (mostly comparative) studies of various statins. It has demonstrated the benefits of rosuvastatin in terms of normalization of lipid profile, inflammatory markers, and coronary or cerebrovascular atherosclerosis regression. This makes rosuvastatin medications promising for the prevention of severe organ complications at all atherosclerosis stages.

статинырозувастатинлипид-снижающее и плейотропное действиямеждународная программа GALAXYStatinsrosuvastatinlipid-lowering and pleiotropic effectsGALAXY international programmeReferencesRoss R. The pathogenesis of atherosclerosis — an update. N Engl J Med 1986; 314: 488-500.Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med 1986; 314: 488-500.Ross R. Atherosclerosis — An Inflammatory Disease. N Engl J Med 1999; 340: 115-26.Ross R. Atherosclerosis — An Inflammatory Disease. N Engl J Med 1999; 340: 115-26.Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-8.Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-8.Van der Wal AC, Das PK, Bentzvan de Berg D, et al. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-70.Van der Wal AC, Das PK, Bentzvan de Berg D, et al. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-70.Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven 1996; 585-94.Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven 1996; 585-94.Raines EW, Rosenfeld ME, Ross R. The role of macrophages. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven 1996; 539-55.Raines EW, Rosenfeld ME, Ross R. The role of macrophages. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven 1996; 539-55.Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 2. Philadelphia: Lippincott-Raven 1996; 492-510.Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 2. Philadelphia: Lippincott-Raven 1996; 492-510.Бритов А.Н., Гомазков О.А. Биохимический, структурный и клинический анализ плейотропных эффектов статинов. Кардиоваск тер профил 2009; 5: 92-102.Бритов А.Н., Гомазков О.А. Биохимический, структурный и клинический анализ плейотропных эффектов статинов. Кардиоваск тер профил 2009; 5: 92-102.Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 2004; 364(9438): 937- 52.Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 2004; 364(9438): 937- 52.Сусеков А.Н. Программа клинических исследований розувастатина GALAXY. Сердце: журнал для практикующих врачей 2005; 4(4): 214-9.Сусеков А.Н. Программа клинических исследований розувастатина GALAXY. Сердце: журнал для практикующих врачей 2005; 4(4): 214-9.Nissen SE, Tuzcu EM, Schoenhagen P, et al. (REVERSAL Investigators). Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 9(291): 1071-80.Nissen SE, Tuzcu EM, Schoenhagen P, et al. (REVERSAL Investigators). Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 9(291): 1071-80.Nissen SE, Nicholls SJ, Sipahy I et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13): 1556-65.Nissen SE, Nicholls SJ, Sipahy I et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13): 1556-65.Crouse JR III, Raichlen JS, Riley WA. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA 2007; 297: 1344-53,8.Crouse JR III, Raichlen JS, Riley WA. Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA 2007; 297: 1344-53,8.Cholesterol Treatment Trialist (CTT) Collaborators. Lancet 2005; 757-67.Cholesterol Treatment Trialist (CTT) Collaborators. Lancet 2005; 757-67.Kjekshus J, Apetrei E, Barrios V, et al. for the CORONA Group. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248-61.Kjekshus J, Apetrei E, Barrios V, et al. for the CORONA Group. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248-61.Fellstrom BC, Jardine AG, Schmieder MD et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med 2009; 360(14): 1395-407.Fellstrom BC, Jardine AG, Schmieder MD et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med 2009; 360(14): 1395-407.Ridker PM and Jupiter Study. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108(19): 2292-7.Ridker PM and Jupiter Study. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108(19): 2292-7.Ridker P, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008; 359: 2195-207.Ridker P, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Eng J Med 2008; 359: 2195-207.Hlatky MA. Expanding the Orbit of Primary Prevention — Moving beyond JUPITER. N Engl J Med 2008; 359: 2280-2.Hlatky MA. Expanding the Orbit of Primary Prevention — Moving beyond JUPITER. N Engl J Med 2008; 359: 2280-2.Schuster H, Barter PJ, Cheung RC, et al. for the MERCURY I Study Group: Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-13.Schuster H, Barter PJ, Cheung RC, et al. for the MERCURY I Study Group: Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-13.Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metabol 2005; 7: 430-8.Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metabol 2005; 7: 430-8.Ballantyne C, Raichlen J, Cain VA, et al. Effect of switching highand very high-risk patients to rosuvastatin from atorvastatin or simvastatin on achievement of new ATP III goals: MERCURY II. Atherosclerosis Supplements 2005; 6(1): W16-P-003.Ballantyne C, Raichlen J, Cain VA, et al. Effect of switching highand very high-risk patients to rosuvastatin from atorvastatin or simvastatin on achievement of new ATP III goals: MERCURY II. Atherosclerosis Supplements 2005; 6(1): W16-P-003.Ballantyne CM, Raichlen JS, Cain VA. Statin Therapy Alters the RelationshipBetween Apolipoprotein B and Low-DensityLipoprotein Cholesterol and Non-HighDensityLipoprotein Cholesterol Targets in High-Risk PatientsThe MERCURY II (Measuring EffectiveReductions in Cholesterol Using Rosuvastatin therapy) Trial. JACC 2008; 52: 626-32.Ballantyne CM, Raichlen JS, Cain VA. Statin Therapy Alters the RelationshipBetween Apolipoprotein B and Low-DensityLipoprotein Cholesterol and Non-HighDensityLipoprotein Cholesterol Targets in High-Risk PatientsThe MERCURY II (Measuring EffectiveReductions in Cholesterol Using Rosuvastatin therapy) Trial. JACC 2008; 52: 626-32.Jones PH, Davidson MH, Stein EA, et al.). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92(2): 152-60.Jones PH, Davidson MH, Stein EA, et al.). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92(2): 152-60.Nissen SE, Nicholls SJ, Sipahy I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13): 1556-65.Nissen SE, Nicholls SJ, Sipahy I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295(13): 1556-65.Kjekshus J, Apetrei E, Barrion V, et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 2007; 357 doi 10.1056/NEJMoa0706201.Kjekshus J, Apetrei E, Barrion V, et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 2007; 357 doi 10.1056/NEJMoa0706201.Crouse JRIII, Raichlen JS, Riley WA, et al. for the METEOR Study Group Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. The METEOR Trial. JAMA 2007; 297:1344-1353. Published online March 25, 2007Crouse JRIII, Raichlen JS, Riley WA, et al. for the METEOR Study Group Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis. The METEOR Trial. JAMA 2007; 297:1344-1353. Published online March 25, 2007Betteridge DJ, Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study. Atheroscler Suppl 2004; 5: 107-8.Betteridge DJ, Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study. Atheroscler Suppl 2004; 5: 107-8.Berne C, Siewert-Delle A, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005; 3: 4-7.Berne C, Siewert-Delle A, URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005; 3: 4-7.

The authors declare that there are no conflicts of interest present.